Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention

Affiliations

¹ Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Geb. 40, Universitätsklinikum des Saarlandes, Homburg/Saar D-66421, Germany ulrich.laufs@uks.eu.
² Lipid Clinic, Hopital de Jolimont, Haine-Saint-Paul, Belgium.
³ Department of Pharmacological and Biomolecular Sciences, University of Milano and Multimedica IRCCS, Milano, Italy.
⁴ Glasgow Clinical Research Facility, Tennent Building, 38 Church Street, Western Infirmary, Glasgow G11 6NT, UK.

Comment

Ulrich Laufs et al. Eur Heart J. 2014.

. 2014 Aug 7;35(30):1996-2000.

doi: 10.1093/eurheartj/ehu228. Epub 2014 Jun 10.

¹ Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Geb. 40, Universitätsklinikum des Saarlandes, Homburg/Saar D-66421, Germany ulrich.laufs@uks.eu.
² Lipid Clinic, Hopital de Jolimont, Haine-Saint-Paul, Belgium.
³ Department of Pharmacological and Biomolecular Sciences, University of Milano and Multimedica IRCCS, Milano, Italy.
⁴ Glasgow Clinical Research Facility, Tennent Building, 38 Church Street, Western Infirmary, Glasgow G11 6NT, UK.

No abstract available

Comment on

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM; IMPROVE-IT Investigators. Cannon CP, et al. Am Heart J. 2008 Nov;156(5):826-32. doi: 10.1016/j.ahj.2008.07.023. Epub 2008 Sep 2. Am Heart J. 2008. PMID: 19061694 Clinical Trial.